ARCT — Arcturus Therapeutics Holdings Inc.

Summary of Arcturus Therapeutics Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2026, Arcturus reported cash, cash equivalents, and restricted cash totaling $213.4 million, down from $232.8 million at the end of 2025.
• Revenue: Quarterly revenue decreased by $27.3 million year-over-year, primarily due to reduced revenue from the CSL collaboration as the company refocuses on its rare disease clinical programs.
• Expenses: R&D expenses decreased by $13.4 million, attributed to lower manufacturing costs and clinical trial expenses related to the LUNAR-COVID program. General and administrative expenses also fell by $1.8 million due to reduced share-based compensation and headcount.
• Cash Runway: The company maintains a cash runway extending beyond the second quarter of 2028.

2. Strategic Updates and Business Highlights

• Cystic Fibrosis (CF) Program: Enrollment has begun in a 12-week Phase II study of ARCT-032, targeting Class I CF mutations. This study is significant as it marks the first time continuous dosing beyond one month has been tolerated in inhaled mRNA therapeutics.
• OTC Deficiency Program: Following a Type C meeting with the FDA, Arcturus received clear guidance on a pivotal pediatric study for ARCT-810, aimed at treating ornithine transcarbamylase deficiency.
• COVID Vaccine: The company’s partner, Meiji, is preparing to manufacture KOSTAIVE, a self-amplifying mRNA COVID vaccine, for the upcoming 2026-2027 season.
• Leadership Expansion: New appointments include Dennis Mulroy as CFO and Dr. Alan Cohen as CMO, enhancing the company's executive team.

3. Forward Guidance and Outlook

• Arcturus is optimistic about advancing its rare disease pipeline, with expectations of achieving meaningful clinical and regulatory milestones throughout 2026.
• The company aims to generate robust clinical data from its ongoing studies, particularly in CF and OTC deficiency, to support future development and regulatory submissions.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The significant drop in revenue raises concerns about the company’s short-term financial health as it transitions focus away from collaborations.
• Competitive Pressures: A competitor recently discontinued its inhaled CFTR mRNA trial, which may raise questions about the viability of similar approaches. However, Arcturus asserts that its technology and delivery methods differ significantly from those of competitors.
• Regulatory Risks: While the FDA has provided guidance, the success of the pediatric program for OTC deficiency hinges on the outcome of ongoing studies and regulatory interactions.

5. Notable Q&A Insights

• OTC Program Development: The FDA emphasized the importance of specific biomarkers (ammonia, glutamine) for the OTC program, with a focus on pediatric patients under six years old.
• Cystic Fibrosis Study Design: The absence of a placebo control in the CF study raises questions about data interpretation. The company is monitoring lung function parameters closely and believes that the established experience of patients with spirometry will mitigate variability concerns.
• Patient Enrollment: The company is expanding enrollment beyond the U.S. to include patients from regions with higher prevalence of Class I mutations, aiming for a balanced mix of U.S. and international participants.
• Future Data Releases: Arcturus anticipates having sufficient data to inform future steps in the CF program by the end of the year, with potential interim results depending on patient progress.

This summary encapsulates the key points from the earnings call, providing a balanced view of Arcturus Therapeutics' current status and future outlook.